





PTEN Polyclonal Antibody

Catalog Number 51-2400 Product data sheet

Species Reactivity

Western Blot (WB)

Details	
Size	200 μg
Host/Isotope	Rabbit / IgG
Class	Polyclonal
Туре	Antibody
Immunogen	A 22 amino acid synthetic peptide derived from the carboxy-terminus of the human PTEN protein. This sequence is 100% conserved with the dog PTEN protein and differs by only one amino acid from the rat and mouse PTEN proteins
Conjugate	Unconjugated
Form	Liquid
Concentration	0.25 mg/mL
Purification	Antigen affinity chromatography
Storage buffer	PBS, pH 7.4
Contains	0.1% sodium azide
Storage Conditions	-20°C

Species reactivity	Human, Mouse
Published species	Mouse, Human, Not Applicable
Tested Applications	Dilution *
ELISA (ELISA)	0.1-1.0 μg/mL
Immunohistochemistry (Paraffin) (IHC (P))	1:50-1:500

Published Applications		
Immunohistochemistry (IHC)	See 5 publications below	
Western Blot (WB)	See 1 publications below	
Immunohistochemistry (Paraffin) (IHC (P))	See 4 publications below	

1-3 µg/mL

Background/Target Information

PTEN was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The PTEN gene is a phosphatidylinositol-3, 4, 5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. PTEN negatively regulates intracellular levels of phosphatidylinositol-3, 4, 5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. PTEN plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Also, PTEN may be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form of PTEN induces less tumor suppressive ability.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.


For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample




^{*} Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.

Product Images For PTEN Polyclonal Antibody



PTEN Antibody (51-2400)

IP-MS enrichment of PTEN (LFQ intensity): PTEN was enriched 169-fold from MCF7 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Product # 90409) and PTEN antibody (Product # 51-2400). See more information on IP-MS verification of antibody selectivity. {IP-MS}




PTEN Antibody (51-2400) in IHC (P)

Immunohistochemistry analysis of PTEN showing staining in the cytoplasm and nucleus of paraffin-embedded human breast carcinoma (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a PTEN polyclonal antibody (Product # 51-2400) diluted in 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.



PTEN Antibody (51-2400) in IHC (P)

Immunohistochemistry analysis of PTEN showing staining in the cytoplasm and nucleus of paraffin-embedded mouse prostate tissue (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a PTEN polyclonal antibody (Product # 51-2400) diluted in 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.



PTEN Antibody (51-2400)


Antibody specificity was demonstrated by CRISPR-Cas9 mediated knockout of target protein. A loss of signal was observed for target protein inPTEN KO cell line compared to control cell line using Anti-PTEN Polyclonal Antibody (Product # 51-2400). {KO}

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The varranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample

NO OTHER WARRANTES, EXPRESS OR MINELD, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BLYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPRIA, REPLACEDING TO FOR REFUND FOR THE NON-CONFORMING PRODUCTS (DIF AT SULTERS IS NO EDULGATION TO REPRIA, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS (S) AT SELLER'S IS NO EDULGATION TO REPRIA, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS, IS AT SELLER'S LIVING FOR THE NON-CONFORMING PRODUCTS. AS THE RESULT OF (I) ACCIDING THE NON-CONFORMING PRODUCTS (S) A SANATER OR EVENT OF FORCE MADE (S) AT SELLER (S) AND SELLER (S) AN






PTEN Antibody (51-2400) in IHC (P)

Immunohistochemistry analysis of PTEN showing staining in the cytoplasm of paraffin-embedded human prostate carcinoma (right) compared to a negative control without primary antibody (left). To expose target proteins, antigen retrieval was performed using 10mM sodium citrate (pH 6.0), microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a PTEN polyclonal antibody (Product # 51-2400) diluted in 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively in PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.



PTEN Antibody (51-2400) in IHC

Human prostate tissue stained with rabbit anti-PTEN antibody (Product # 18-0256).



PTEN Antibody (51-2400) in WB

Knockout of PTEN was achieved by CRISPR-Cas9 genome editing using LentiArray™ Lentiviral sgRNA (Product # A32042, Assay ID CRISPR766883_LV) and LentiArray Cas9 Lentivirus (Product # A32064). Western blot analysis of PTEN was performed by loading 30 µg of HeLa Cas9 (Lane 1) andHeLa PTEN KO (Lane 2) whole cell extracts. The samples were electrophoresed using NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gel (Product # NP0322BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with Anti-PTEN Polyclonal Antibody (Product # 51-2400, 1:1000 dilution) and Goat anti-Rabbit IgG (Heavy Chain) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036, 1:5000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using SuperSignal™ West Dura Extended Duration Substrate (Product # 34076). Loss of signal upon CRISPR mediated knockout (KO) using the LentiArray™ CRISPR product line confirms that antibody is specific to PTEN.An uncharacterized band observed around ~130 kDa in both samples.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The varranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample unstant of the product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample unstant of the product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample.

NO OTHER WARRANTIES, EXPRESS OR MINELD, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPRIA, PERIOLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCTS DATE IN ADMINISTER, OR WITHOUT OF THE PROPAGE AND THE PROPAGE OR THE PURPOR OF REPRODUCTS AS THE RESULT OF (I) ACCIDENT OF FORCE MALEYER, (II) MISSISSE, FAULT OR NEGLECON TO THE PROPAGE OR REPUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT OF FORCE MALEYER, (III) MISSISSE, FAULT OR NEGLECON TO THE PRODUCTS AS THE RESULT OF (III) ACCIDENT OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) MIPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used and or in any objectives, including without limitation, unathorized commercial uses, in vity to design of consumption by or appointment or animals.



5 Immunohistochemisti	v References
Species / Dilution	Summary
opeoice, 2.i.uiieii	51-2400 was used in Immunohistochemistry to show that EphA2 may be a target of miR-200a in AC and in pStage I/II cancers that exhibit AKT2 CNI.
Human / 1:200	International journal of clinical and experimental pathology (2020; 13: 2201) "EphA2, a possible target of miR-200a, functions through the AKT2 pathway in human lung carcinoma." Author(s):Tsubochi H,Minegishi K,Goto A,Nakamura R,Matsubara D,Dobashi Y PubMed Article URL:http://www.ncbi.nlm.nih.gov/pubmed/32922621
Human / 1:50	Clinical cancer research: an official journal of the American Association for Cancer Research (2002; 8: 1178) "Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation." Author(s):Soria JC,Lee HY,Lee JI,Wang L,Issa JP,Kemp BL,Liu DD,Kurie JM,Mao L,Khuri FR PubMed Article URL:http://www.ncbi.nlm.nih.gov/pubmed/12006535
Human / 1:200	Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2013; 22: 1984) "Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study." Author(s):Zu K,Martin NE,Fiorentino M,Flavin R,Lis RT,Sinnott JA,Finn S,Penney KL,Ma J,Fazli L,Gleave ME,Bismar TA,
	Stampfer MJ,Pollak MN,Loda M,Mucci LA,Giovannucci E PubMed Article URL:http://dx.doi.org/10.1158/1055-9965.EPI-13-0349
Mouse / Not Cited	51-2400 was used in Immunohistochemistry to show that mechanistic target of rapamycin complex 1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity.
	Nature (2017; 547: 109) "mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer." Author(s):Zabala-Letona A,Arruabarrena-Aristorena A,Martín-Martín N,Fernandez-Ruiz S,Sutherland JD,Clasquin M, Tomas-Cortazar J,Jimenez J,Torres I,Quang P,Ximenez-Embun P,Bago R,Ugalde-Olano A,Loizaga-Iriarte A,Lacasa-Viscasillas I,Unda M,Torrano V,Cabrera D,van Liempd SM,Cendon Y,Castro E,Murray S,Revandkar A,Alimonti A,Zhang Sarnett A,Lein G,Pirman D,Cortazar AR,Arreal L,Prudkin L,Astobiza I,Valcarcel-Jimenez L,Zuñiga-García P,Fernandez-Dominguez I,Piva M,Caro-Maldonado A,Sánchez-Mosquera P,Castillo-Martín M,Serra V,Beraza N,Gentilella A,Thomas G, Azkargorta M,Elortza F,Farràs R,Olmos D,Efeyan A,Anguita J,Muñoz J,Falcón-Pérez JM,Barrio R,Macarulla T,Mato JM, Martinez-Chantar ML,Cordon-Cardo C,Aransay AM,Marks K,Baselga J,Tabernero J,Nuciforo P,Manning BD,Marjon K, Carracedo A PubMed Article URL:http://dx.doi.org/10.1038/nature22964
Mouse / Not Cited	51-2400 was used in Immunohistochemistry to uncover a proto-oncogenic microRNA-dependent network for phosphatase and tensin homologue deleted on chromosome 10 regulation and defined the MCM7 locus as critical in initiating prostate tumourigenesis.
	Science signaling (2010; 3:) "Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation." Author(s):Poliseno L,Salmena L,Riccardi L,Fornari A,Song MS,Hobbs RM,Sportoletti P,Varmeh S,Egia A,Fedele G, Rameh L,Loda M,Pandolfi PP PubMed Article URL:http://dx.doi.org/10.1126/scisignal.2000594
1 Western Blot Referen	ces
Species / Dilution	Summary
Human / 1:300	Cancer research (2003; 63: 1382) "Growth and molecular profile of lung cancer cells expressing ectopic LKB1: down-regulation of the phosphatidylinositol 3'-phosphate kinase/PTEN pathway." Author(s):Jimenez AI,Fernandez P,Dominguez O,Dopazo A,Sanchez-Cespedes M PubMed Article URL:http://www.ncbi.nlm.nih.gov/pubmed/12649203
4 Immunohistochemisti	y (Paraffin) References
Species / Dilution	Summary
	51-2400 was used in Immunohistochemistry on paraffin embedded tissues to demonstrate that immune surveillance of senescent tumour cells can be suppressed in specific genetic backgrounds but also evoked by pharmacological treatments.
Mouse / Not Cited	Cell reports (2014; 9: 75) "Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity." Author(s):Toso A,Revandkar A,Di Mitri D,Guccini I,Proietti M,Sarti M,Pinton S,Zhang J,Kalathur M,Civenni G,Jarrossay D Montani E,Marini C,Garcia-Escudero R,Scanziani E,Grassi F,Pandolfi PP,Catapano CV,Alimonti A PubMed Article URL:http://dx.doi.org/10.1016/j.celrep.2014.08.044

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The varranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample unstant of the product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample unstant of the product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample.

NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCTS) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR REFUND FOR REFUND FOR THE NON-CONFORMING PRODUCTS) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR REFOLDETS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FALLY OR NEGLEGIESTOE OF THE PRODUCTS. In A MANNER FOR WHICH THEY WERE NOT DESPONDED STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, or vitro or in vivo therapeutic uses, or any type of consumption by or application to human or animals.



	512400 was used in immunohistochemistry - paraffin section to demonstrate that PTEN loss results in ADAM17 and NOTCH signaling in prostate cancer cells	
Mouse / Not Cited	Nature communications (2016; 7:) "Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence." Author(s):Revandkar A,Perciato ML,Toso A,Alajati A,Chen J,Gerber H,Dimitrov M,Rinaldi A,Delaleu N,Pasquini E,D'Antuono R,Pinton S,Losa M,Gnetti L,Arribas A,Fraering P,Bertoni F,Nepveu A,Alimonti A PubMed Article URL:http://dx.doi.org/10.1038/ncomms13719	
Not Applicable / Not Cited	51-2400 was used in immunohistochemistry - paraffin section to assess PTEN expression by immunopathology	
	Methods in molecular biology (Clifton, N.J.) (2016; 1388: 23) "Immunopathologic Assessment of PTEN Expression." Author(s):Castillo-Martin M,Thin TH,Collazo Lorduy A,Cordon-Cardo C PubMed Article URL:http://dx.doi.org/10.1007/978-1-4939-3299-3_3	
Human / Not Cited	51-2400 was used in Immunohistochemistry on paraffin embedded tissues to study the mechanisms by which mitochondrial metabolism supports cancer anabolism.	
	Nature genetics (2018; 50: 219) "Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer." Author(s):Chen J,Guccini I,Di Mitri D,Brina D,Revandkar A,Sarti M,Pasquini E,Alajati A,Pinton S,Losa M,Civenni G,Catapano CV,Sgrignani J,Cavalli A,D'Antuono R,Asara JM,Morandi A,Chiarugi P,Crotti S,Agostini M,Montopoli M,Masgras I,Rasola A,Garcia-Escudero R,Delaleu N,Rinaldi A,Bertoni F,Bono J,Carracedo A,Alimonti A PubMed Article URL:http://dx.doi.org/10.1038/s41588-017-0026-3	

 $\label{thm:condition} For \, Research \, Use \, Only. \, \, Not \, for \, use \, in \, diagnostic \, procedures. \, Not \, for \, resale \, without \, express \, authorization.$

Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation in the Buyer. Any model or sample furnished to Design is merely illustrated or the general type and quality of goods and does not represent that any Product will combine to such model or sample furnished to Design is merely illustrated or the general type and quality of goods and does not represent that any Product will combine the support of the period of the product of the period of the

NO OTHER WARRANTIES, EXPRESS OR IMPLED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACE OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FALLT OR NEGLEGIENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DOES AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, or vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.

